HRT Financial’s Virax Biolabs VRAX Stock Holding History

HRT Financial’s Portfolio VRAX Stock Details VRAX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-2,403	Closed	-$36K	–	4123
2025 Q3	$36K	Buy	+2,403	New	+$45.8K	﹤0.01%	2635
2025 Q2	–	Sell	-540	Closed	-$15K	–	3597
2025 Q1	$15K	Buy	+540	New	+$23.8K	﹤0.01%	2325
2024 Q3	–	Sell	-1,027	Closed	-$29K	–	3198
2024 Q2	$29K	Buy	+1,027	New	+$25.4K	﹤0.01%	1899
2023 Q2	–	Sell	-62	Closed	-$10K	–	3355
2023 Q1	$10K	Buy	+62	New	+$12K	﹤0.01%	2252

Other funds holding VRAX

XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

National Bank of Canada Montreal, Quebec, Canada $112B AUM 31.26% 1-Year Est. Return

FFA

Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Northwestern Mutual Wealth Management Milwaukee, Wisconsin $162B AUM 16.35% 1-Year Est. Return

HRT Financial's VRAX Position: Q4 2025 in Review

HRT Financial sold out of Virax Biolabs (VRAX) in Q4 2025, closing a stake of 2,403 shares — an estimated $36K sold.

HRT Financial first reported a position in VRAX in Q1 2023 and held it in 4 quarters. The position peaked at $36K in Q3 2025. 5 funds tracked by Wall St. Rank hold VRAX as of Q4 2025.

HRT Financial reported no remaining Virax Biolabs position as of Q4 2025 after selling out during the quarter.
HRT Financial sold 2,403 Virax Biolabs shares in Q4 2025, an estimated $36K.
HRT Financial first reported a position in Virax Biolabs in Q1 2023 and held it in 4 quarters.
HRT Financial's Virax Biolabs position peaked at $36K in Q3 2025.
5 funds tracked by Wall St. Rank held Virax Biolabs as of Q4 2025.

Based on HRT Financial's 13F filing for Q4 2025, filed 12 Feb 2026.